In the largest study in this population to date, a CALGB and Breast Cancer Intergroup study, 33 patients 65 and older with early stage breast cancer were randomly assigned to either standard treatment doxorubicin and cyclophosphamide AC for four cycles or cyclophosphamide, methotrexate, and 5 fluorouracil CMF for six cycles or to an experimental arm of single agent capecitabine for six cycles
stromectol 6 mg tablet
